Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Eli Lilly licenses MacroGenics' teplizumab

MacroGenics (Rockville, Md.) granted LLY exclusive worldwide rights to develop and commercialize teplizumab. The humanized

Read the full 152 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE